Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study

Alessandra Buja; Andrea Bardin; Giovanni Damiani; Manuel Zorzi; Chiara De Toni; Riccardo Fusinato; Romina Spina; Antonella Vecchiato; Paolo Del Fiore; Simone Mocellin; Vincenzo Baldo; Massimo Rugge; Carlo Riccardo Rossi

doi:10.3389/fonc.2021.737399

Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study

Front Oncol. 2021 Nov 16:11:737399. doi: 10.3389/fonc.2021.737399. eCollection 2021.

Authors

Alessandra Buja¹, Andrea Bardin¹, Giovanni Damiani^{2

3

4}, Manuel Zorzi⁵, Chiara De Toni¹, Riccardo Fusinato¹, Romina Spina⁶, Antonella Vecchiato⁶, Paolo Del Fiore⁶, Simone Mocellin^{6

7}, Vincenzo Baldo¹, Massimo Rugge^{5

8}, Carlo Riccardo Rossi⁷

Affiliations

¹ Department of Cardiologic, Vascular and Thoracic Sciences, and Public Health, University of Padua, Padua, Italy.
² Clinical Dermatology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Ortopedico Galeazzi, Milan, Italy.
³ Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
⁴ PhD Program in Pharmacological Sciences, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
⁵ Veneto Tumor Registry - Azienda Zero, Padova, Italy.
⁶ Surgical Oncology Unit, Veneto Institute of Oncology IOV-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padova, Italy.
⁷ Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padova, Italy.
⁸ Department of Medicine DIMED, Surgical Pathology & Cytopathology Unit, University of Padova, Padova, Italy.

Abstract

Introduction: Among white people, the incidence of cutaneous malignant melanoma (CMM) has been increasing steadily for several decades. Meanwhile, there has also been a significant improvement in 5-year survival among patients with melanoma. This population-based cohort study investigates the five-year melanoma-specific survival (MSS) for all melanoma cases recorded in 2015 in the Veneto Tumor Registry (North-Est Italian Region), taking both demographic and clinical-pathological variables into consideration.

Methods: The cumulative melanoma-specific survival probabilities were calculated with the Kaplan-Meier method, applying different sociodemographic and clinical-pathological variables. Cox's proportional hazards model was fitted to the data to assess the association between independent variables and MSS, and also overall survival (OS), calculating the hazard ratios (HR) relative to a reference condition, and adjusting for sex, age, site of tumor, histotype, melanoma ulceration, mitotic count, tumor-infiltrating lymphocytes (TIL), and stage at diagnosis.

Results: Compared with stage I melanoma, the risk of death was increased for stage II (HR 3.31, 95% CI: 0.94-11.76, p=0.064), almost ten times higher for stage III (HR 10.51, 95% CI: 3.16-35.02, p<0.001), and more than a hundred times higher for stage IV (HR 117.17, 95% CI: 25.30-542.62, p<0.001). Among the other variables included in the model, the presence of mitoses and histological subtype emerged as independent risk factors for death.

Conclusions: The multivariable analysis disclosed that older age, tumor site, histotype, mitotic count, and tumor stage were independently associated with a higher risk of death. Data on survival by clinical and morphological characteristics could be useful in modelling, planning, and managing the most appropriate treatment and follow-up for patients with CMM.

Keywords: cancer survival; clinical characteristics; epidemiology; melanoma; survival.